Trans-Tranilast T2270
Specifications
| 1mg/5mg/10mg/25mg/50mg/100mg |
Bioactivity:
Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. It was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of al
CAS nr:
70806-55-2
Purity:
98%
Molecular Weight:
327,33
SMILES:
COc1c(cc(cc1)/C=C/C(=O)Nc1c(cccc1)C(=O)O)OC
Formula:
C18H17NO5
Pathway:
Endocrinology/Hormones
Target:
RAAS
